Corporate

Cravath represented the underwriters in connection with the $2 billion registered notes offering of Hewlett Packard Enterprise Company, an industry leading technology company. The transaction closed on March 23, 2026.

Cravath represented Rogers Communications Inc. in connection with its $750 million registered fixed‑to‑fixed rate subordinated notes offering. Rogers Communications is Canada's leading communications, sports and entertainment company. The transaction closed on March 27, 2026.

Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $1.35 billion of credit facilities made available to subsidiaries of Versigent Limited, a global leader in the design, development and manufacture of low voltage and high voltage electrical architectures and the holding company for Aptiv PLC’s Electrical Distribution Systems segment, which Aptiv PLC spun off into a separate, independent, publicly traded company. The proceeds were used to partially finance the spin‑off. The credit facilities consisted of a $500 million term loan facility and an $850 million revolving credit facility. The transaction closed on November 26, 2025.

Cravath represented Akastor ASA in connection with its indirect 50% owned affiliate HMH Holding Inc.’s initial public offering of 10,520,000 shares of its Class A common stock at $20.00 per share. The shares began trading on The Nasdaq Global Select Market on April 1, 2026, under the ticker symbol “HMH.” The transaction closed on April 2, 2026.

On March 31, 2026, Biogen Inc. and Apellis Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE®. Cravath is representing Biogen in connection with the transaction.

On April 7, 2026, Intellectual Asset Management (“IAM”) published an article written by Cravath partner David J. Kappos and associate Noa M. Ma entitled, “Why Global FRAND Rate‑Setting Must Require SEP Owner Consent.” The article discusses why courts should only set global FRAND royalty rates with patent owner consent, arguing that forced rate‑setting risks undermining the balance of rights that underpins SEP licensing.

Four Cravath attorneys were selected to serve on Law360’s 2026 Editorial Advisory Boards: partners Ryan J. Patrone (Capital Markets), Claudia J. Ricciardi (Mergers & Acquisitions) and Jihyun Chung (Private Equity) and of counsel Scott B. Reents (Legal Tech). As Editorial Advisory Board members, they will provide feedback on Law360’s coverage and expert insight on how best to shape future coverage.

On March 31, 2026, Cravath published the latest edition of its Artificial Intelligence Developments Newsletter, which includes a high‑level review of activity across technical, regulatory, legal, and market areas of AI over the last month.

Cravath partners Jin‑Kyu Baek, Nicholas A. Dorsey and Lauren Roberta Kennedy were featured in the 2026 edition of “Practice Perspectives: Vault’s Guide to Legal Practice Areas,” which highlights the experiences of practicing lawyers in more than 20 different areas of the law and is published annually.

The Chambers USA Awards 2026 named Cravath a finalist in its Antitrust and Corporate/M&A practice area categories. The awards celebrate the achievements of leading law firms and lawyers operating across the United States, recognizing those who demonstrate excellence in legal practice, innovation and sustained performance at the highest level. The winners will be announced on June 11, 2026 at an awards ceremony in New York.